Prevalence of high-risk metabolic dysfunction-associated fatty liver disease (MASH) according to the FAST® index in a group of diabetic patients
Introduction and Objectives: Diabetes is a high-risk condition for the progression of metabolic-associated fatty liver disease (MASLD). The FAST index combines the FibroScan® and AST to predict the risk of high-risk metabolic dysfunction-associated steatohepatitis (MASH). Objective: determine the pr...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268125000407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction and Objectives: Diabetes is a high-risk condition for the progression of metabolic-associated fatty liver disease (MASLD). The FAST index combines the FibroScan® and AST to predict the risk of high-risk metabolic dysfunction-associated steatohepatitis (MASH). Objective: determine the proportion of diabetic patients at high risk of MASH according to the FAST index. Materials and Patients: Observational, cross-sectional study to estimate prevalence. Diabetic patients who agreed to undergo FibroScan® and liver biochemistry profile were included. The FAST® index was calculated (<0.35 no risk; 0.35 to 0.67 indeterminate; ≥ 0.67 high-risk NASH). Descriptive statistics were used, and a correlation matrix was performed using Pearson's test, with a p value < 0.05 considered significant. Results: 298 patients were evaluated, 195 (64.5%) women, mean age 55.6±10.8 years, of whom 284 (95.3%) agreed to undergo FibroScan® study, 109 (38.4%) presented steatosis: S1 in 34 (12%), S2 in 33 (11.6%) and S3 in 42 (14.8%). 155 (56.4%) had fibrosis: F1 in 42 (14.8%), F2 in 40 (14.1%), F3 in 26 (9.2%) and F4 in 47 (16.5%). 261 (87.6%) patients had recent determination of aminotransferases; according to the FAST® index: without risk= 200 (76.6%), indeterminate= 31 (11.9%), and with high risk= 30 (11.5%). There was a strongly positive correlation between a higher FAST index and a higher probability of having a higher degree of fibrosis (r=0.702, p<0.0001). The correlation matrix is shown in Table 1 Conclusions: The prevalence of MASH is considerable in patients with diabetes; the factors that determine this risk in this population are not yet clear. FAST® appears to be a non-invasive tool for making decisions regarding MASH. |
|---|---|
| ISSN: | 1665-2681 |